Table 2 Characteristics of LEOSS and UKD patients with CP treatment.
Variable | LEOSS | UKD | LEOSS | UKD |
|---|---|---|---|---|
Total | 156 | 55 | 46 | 23 |
Yes/total available values | ||||
Comorbidities | ||||
Myocardial infarction | 11/153 | 1 | 5 (45.5) | 0 |
Chronic heart failure | 4/153 | 3 | 2 (50) | 3 (100) |
Coronary Artery disease | 23/153 | 3 | 15 (65.2) | 2 (66.7) |
Chronic pulmonary disease | 11/154 | 2 | 8 (72.7) | 0 |
Malignancies | ||||
Leukemia | 9/154 | 0 | 2 (22.2) | |
Lymphoma | 15/153 | 1 | 4 (26.6) | 0 |
Solid tumor | 10/149 | 4 | 6 (60) | 4 (100) |
Previous stem cell transplantation | 4/149 | 2 | 1 (25) | 1 (50) |
SCID | n/a | 1 | n/a | 0 |
Solid organ transplantation | 14/153 | 8 | 5 (35.7) | 2 (25) |
Heart | 3 | 1 | 0 | 0 |
Kidney | 11 | 7 | 5 (45.5) | 2 (28.6) |
Diabetes mellitus | ||||
No complications | 25/155 | 0 | 9 (36) | |
Complications | 15/153 | 1 | 10 (71.4) | 0 |
Acute Kidney injury | 20/150 | 5 | 7 (35) | 1 (20) |
Chronic kidney disease | 36/151 | 44 | 16 (44.4) | 21 (47.7) |
Dialysis | 5/150 | 13 | 3 (60) | 7 (53.8) |
New renal dialysis during CR | 29/110 | 0 | 21 (72.4) | 0 |
Autoimmune disease | n/a | 8 | 4 (50) | |
Vasculitis | n/a | 4 | 4 (100) | |
HIV (CD4 > 500 / µl) | n/a | 1 | 0 | |
Immunosuppressive therapy | 34/152 | 17 | 11 (32.3) | 7 (41.2) |
New O2 supplementation during CO | 89/153 | 6 | 25 (28) | 3 (50) |
Prior O2 (during UC) | 1/152 | |||
Thrombo-embolic complications | ||||
(TVT, PE, abdominal thrombosis) | 23/153 | 0 | 7 (30.4) | 0 |
Other therapies | ||||
Remdesivir | 39/151 | 11 | 10 (25.6) | 2 (18.2) |
Steroids High | 60/153 | 44 | 21 (35) | 16 (36.4) |
Tocilizumab | 7/141 | 4 | 5 (71.4) | 2 (50) |
